Briggs Morrison - Apr 1, 2022 Form 4/A - Amendment Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President, Head of R&D, Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Stock symbol
SNDX
Transactions as of
Apr 1, 2022
Transactions value $
$530,446
Form type
4/A - Amendment
Date filed
4/13/2022, 04:09 PM
Date Of Original Report
Apr 5, 2022
Previous filing
Feb 3, 2022
Next filing
Apr 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $508K +70.5K +395.52% $7.20 88.4K Apr 1, 2022 Direct F1
transaction SNDX Common Stock Options Exercise $22.5K +3.13K +17.54% $7.20 21K Apr 4, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -70.5K -100% $0.00* 0 Apr 1, 2022 Common Stock 70.5K $7.20 Direct F1, F2
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -3.13K -100% $0.00* 0 Apr 4, 2022 Common Stock 3.13K $7.20 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date.
F2 This option is fully vested.